CLINICAL TRIALS PROFILE FOR TYSABRI
✉ Email this page to a colleague
All Clinical Trials for TYSABRI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00027300 ↗ | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Completed | Elan Pharmaceuticals | Phase 3 | 2001-11-01 | The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. |
| NCT00027300 ↗ | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Completed | Biogen | Phase 3 | 2001-11-01 | The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. |
| NCT00030966 ↗ | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Completed | Elan Pharmaceuticals | Phase 3 | 2002-01-01 | The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS). |
| NCT00030966 ↗ | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Completed | Biogen | Phase 3 | 2002-01-01 | The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS). |
| NCT00083759 ↗ | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | Terminated | Elan Pharmaceuticals | Phase 2 | 2004-05-01 | The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells are thought to cause damage in the joints leading to the symptoms of RA. |
| NCT00083759 ↗ | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | Terminated | Biogen | Phase 2 | 2004-05-01 | The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells are thought to cause damage in the joints leading to the symptoms of RA. |
| NCT00097760 ↗ | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | Completed | Elan Pharmaceuticals | Phase 2 | 2003-06-01 | The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TYSABRI
Condition Name
Clinical Trial Locations for TYSABRI
Trials by Country
Clinical Trial Progress for TYSABRI
Clinical Trial Phase
Clinical Trial Sponsors for TYSABRI
Sponsor Name
